Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.
This meta-analysis examined the efficacy and safety outcomes of post PCI patients treated with extended vs. standard DAPT duration stratified by DAPT score stratum.
The FIND FH is a machine learning model that identified a large number of individuals with probable FH who had not previously been diagnosed in two distinct types of large medical databases.
The LOOP study used implanted loop recorders to detect previously unknown AF and determined AF burden, progression and symptoms in in elderly patients from the general population with CV risk factors.
Applying the PEGeD algorithm (low C-PTP with D-dimer <1000 ng/mL and moderate C-PTP with D-dimer <500 ng/mL) to rule out PE identified more individuals with low PE risk and reduced use of imaging.
AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.
This post-doc analysis of the ENGAGE AF-TIMI 48 trial showed that the effects of edoxaban vs warfarin on ischemic, bleeding and net clinical outcomes were independent of the degree of comorbidities in patients with AF.
PARAGON-HF data suggest that patients with HFpEF with a recent hospitalization have higher rehospitalization rates than those with more distant or no hospitalization, and they may respond better to sacubitril/valsartan.
AHA 2019 Analyses of the DAPA-HF trial evaluated the effect of dapagliflozin across the age spectrum and based on symptoms, physical and social limitations and QoL at baseline.
AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.
AHA 2019 The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.
AHA 2019 The Treat Stroke to Target (TST) trial randomized patients with ischemic stroke or TIA with evidence of atherosclerosis to one of two LDL-c targets and found a benefit of the lower target.